Posted by Michael Wonder on 30 May 2024
ICER publishes evidence report on treatment for chronic obstructive pulmonary disease
30 May 2024 - Ensifentrine has a novel mechanism of action for an inhaled therapy; treatment would achieve common thresholds for cost effectiveness if priced between $7,500 to $12,700/year.
The ICER today posted its revised evidence report assessing the comparative clinical effectiveness and value of ensifentrine (Verona Pharma) for the treatment of chronic obstructive pulmonary disease.
